RxDoctor Payments Data

Thomas Lemay, MD

Interventional Cardiology · Natchez, MSNPI 1295730224

Payments from drug & device makers

$888in general payments, 2019–2025

Across 52 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$620
  • Pfizer$50
  • Boehringer Ingelheim$49
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$43
  • Astellas Pharma US Inc$39
  • Boston Scientific$31
  • plus $56 from 4 others

What the payments were for

  • Food & beverage$888100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$888 in reported general payments places this provider in the 0th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$344,657
Medicare patients
1,096
Services billed
3,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$325,149
XareltoRivaroxaban261$269,594
EntrestoSacubitril/Valsartan105$130,771
FarxigaDapagliflozin Propanediol48$53,770
JardianceEmpagliflozin14$22,919
Repatha SureclickEvolocumab23$22,169
LinzessLinaclotide21$20,507
Bumetanide476$18,023
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,998
Metoprolol Succinate577$10,472
Doxazosin Mesylate442$8,350
Bisoprolol Fumarate415$7,645
JanumetSitagliptin Phos/Metformin Hcl19$7,390
Amiodarone Hcl362$7,128
Losartan Potassium736$6,473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$50$325,149342 claims
Johnson & JohnsonXarelto$15$269,594261 claims
NovartisEntresto$620$130,771105 claims
Boehringer IngelheimJardiance$49$22,91914 claims
MerckJanumet$18$7,39019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Natchez

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →